VIENNA, Sept 5 (Reuters) - CV Therapeutics Inc’s (CVTX.O: Quote, Profile, Research) key angina drug Ranexa has a beneficial effect on heart arrhythmias, a finding which may lay to rest concerns about the product’s safety, researchers said on Wednesday.
